Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases
- PMID: 39226901
- DOI: 10.1016/j.immuni.2024.08.005
Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases
Abstract
Pro-inflammatory autoantigen-specific CD4+ T helper (auto-Th) cells are central orchestrators of autoimmune diseases (AIDs). We aimed to characterize these cells in human AIDs with defined autoantigens by combining human leukocyte antigen (HLA)-tetramer-based and activation-based multidimensional ex vivo analyses. In aquaporin4-antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) patients, auto-Th cells expressed CD154, but proliferative capacity and pro-inflammatory cytokines were strongly reduced. Instead, exhaustion-associated co-inhibitory receptors were expressed together with FOXP3, the canonical regulatory T cell (Treg) transcription factor. Auto-Th cells responded in vitro to checkpoint inhibition and provided potent B cell help. Cells with the same exhaustion-like (ThEx) phenotype were identified in soluble liver antigen (SLA)-antibody-autoimmune hepatitis and BP180-antibody-positive bullous pemphigoid, AIDs of the liver and skin, respectively. While originally described in cancer and chronic infection, our data point to T cell exhaustion as a common mechanism of adaptation to chronic (self-)stimulation across AID types and link exhausted CD4+ T cells to humoral autoimmune responses, with implications for therapeutic targeting.
Keywords: CD154; CD4 T cell exhaustion; Foxp3; MOGAD; antigen-reactive T cell enrichment, ARTE; autoantigen-specific T cells; autoimmune disease; autoimmune hepatitis; bullous pemphigoid; neuromyelitis optica.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.N. is a current employee of Cellerys AG. F.L. discloses speaker honoraria from Grifols, Teva, Biogen, Bayer, Roche, Novartis, and Fresenius; travel funding from Merck, Grifols, and Bayer; and is serving on advisory boards for Roche, Biogen, and Alexion. R.M. has received unrestricted grants from Biogen, Novartis, Roche, and Third Rock and honoraria for advisory roles and lectures from Roche, Novartis, Biogen, Genzyme, Neuway, CellProtect, Third Rock, and Teva. He is a patent holder and co-holder on the following patents: daclizumab in MS (held by NIH), JCV VP1 for vaccination against PML; JCV-specific neutralizing antibodies to treat PML; and antigen-specific tolerization with peptide-coupled cells, novel autoantigens in MS, and designer neoantigens for tumor vaccination (all held by University of Zurich). He is a co-founder of Abata Therapeutics, Watertown, MA, USA and co-founder and employee of Cellerys AG, Schlieren, Switzerland.
Comment in
-
An autoreactive T cell's perception of a land of plenty.Immunity. 2024 Oct 8;57(10):2258-2260. doi: 10.1016/j.immuni.2024.09.005. Immunity. 2024. PMID: 39383840
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials